Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy
Junhao Li, Lujia Huang, Huiling Zhou, et al.
Acta Pharmacologica Sinica (2022) Vol. 43, Iss. 11, pp. 2749-2758
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Acid‐Ionizable Iron Nanoadjuvant Augments STING Activation for Personalized Vaccination Immunotherapy of Cancer
Fangmin Chen, Tianliang Li, Huijuan Zhang, et al.
Advanced Materials (2022) Vol. 35, Iss. 10
Closed Access | Times Cited: 75
A STING pathway-activatable contrast agent for MRI-guided tumor immunoferroptosis synergistic therapy
Shuai Guo, Wei Xiong, Jiaoyang Zhu, et al.
Biomaterials (2023) Vol. 302, pp. 122300-122300
Closed Access | Times Cited: 47
Smart and versatile biomaterials for cutaneous wound healing
Minxiong Li, Wenzheng Xia, Yi Min Khoong, et al.
Biomaterials Research (2023) Vol. 27, Iss. 1
Open Access | Times Cited: 43
Nanovesicles loaded with a TGF-β receptor 1 inhibitor overcome immune resistance to potentiate cancer immunotherapy
Mengxue Zhou, Jiaxin Wang, Jiaxing Pan, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 39
Beyond Drug Delivery System: Immunomodulatory Layered Double Hydroxide Nanoadjuvants Take an Essential Step Forward in Cancer Immunotherapy
Chaojie Zhu, Jianping Jiang, Yingbo Jia, et al.
Accounts of Materials Research (2023) Vol. 4, Iss. 9, pp. 758-771
Closed Access | Times Cited: 28
Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: A review
Zaigang Zhou, Haoxiang Wang, Jie Li, et al.
International Journal of Biological Macromolecules (2023) Vol. 254, pp. 127911-127911
Closed Access | Times Cited: 27
Nanoparticle-based drug delivery systems to enhance cancer immunotherapy in solid tumors
Jiaxin Zhang, Siyuan Wang, D D Zhang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 23
PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications
Miguel Á. Ortega, Diego Liviu Boaru, Diego De León-Oliva, et al.
Journal of Molecular Medicine (2024) Vol. 102, Iss. 8, pp. 987-1000
Closed Access | Times Cited: 13
The opportunities and challenges of using PD-1/PD-L1 inhibitors for leukemia treatment
Mengdan Xu, Shenglong Li
Cancer Letters (2024) Vol. 593, pp. 216969-216969
Closed Access | Times Cited: 11
Enhancing cancer immunotherapy: Exploring strategies to target the PD-1/PD-L1 axis and analyzing the associated patent, regulatory, and clinical trial landscape
S. S. Kirthiga Devi, S. D. Singh, Ramesh Joga, et al.
European Journal of Pharmaceutics and Biopharmaceutics (2024) Vol. 200, pp. 114323-114323
Closed Access | Times Cited: 10
Mitochondrial metabolism blockade nanoadjuvant reversed immune-resistance microenvironment to sensitize albumin-bound paclitaxel-based chemo-immunotherapy
Zaigang Zhou, Wenjuan Luo, Chunjuan Zheng, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 9, pp. 4087-4101
Open Access | Times Cited: 10
Focus on immune checkpoint PD-1/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy
Kunjing Liu, Qi Sun, Qi Liu, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 154, pp. 113618-113618
Open Access | Times Cited: 34
Targeted protein delivery based on stimuli‐triggered nanomedicine
Jinzhao Liu, Yang Zhou, Qingyang Lyu, et al.
Exploration (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 19
In-situ vaccination immunotherapy of colorectal cancer with STING agonist-integrated supramolecular nanovectors
Xiaoying Liu, Fangmin Chen, Madiha Saeed, et al.
Nano Today (2024) Vol. 56, pp. 102273-102273
Closed Access | Times Cited: 7
Brain gliomas: Diagnostic and therapeutic issues and the prospects of drug-targeted nano-delivery technology
Baoqin Song, Xiu Wang, Lijing Qin, et al.
Pharmacological Research (2024) Vol. 206, pp. 107308-107308
Open Access | Times Cited: 7
Nanomaterials in Immunology: Bridging Innovative Approaches in Immune Modulation, Diagnostics, and Therapy
George-Alexandru Croitoru, Diana-Cristina Pîrvulescu, Adelina-Gabriela Niculescu, et al.
Journal of Functional Biomaterials (2024) Vol. 15, Iss. 8, pp. 225-225
Open Access | Times Cited: 6
Hyperbaric oxygen augments chemodynamic effect induced by probiotic-derived selenium nanoparticles to enhance cancer immune checkpoint blockade therapy
Puze Li, Yuzhu Yao, Xue Chen, et al.
Chemical Engineering Journal (2023) Vol. 474, pp. 145738-145738
Closed Access | Times Cited: 15
Applications of nanotechnology in remodeling the tumour microenvironment for glioblastoma treatment
Yulei Mu, Zhen Zhang, Huiqun Zhou, et al.
Biomaterials Science (2024) Vol. 12, Iss. 16, pp. 4045-4064
Closed Access | Times Cited: 5
Self‐Adaptive Nanoregulator to Mitigate Dynamic Immune Evasion of Pancreatic Cancer
Jiaxing Pan, Yi Lai, Shunan Zhang, et al.
Advanced Materials (2023) Vol. 35, Iss. 47
Closed Access | Times Cited: 12
Engineering Cell-Derived Nanovesicles for Targeted Immunomodulation
Adil Ali Sayyed, Piyush Gondaliya, Irene K. Yan, et al.
Nanomaterials (2023) Vol. 13, Iss. 20, pp. 2751-2751
Open Access | Times Cited: 11
Immunocyte membrane-derived biomimetic nano-drug delivery system: a pioneering platform for tumour immunotherapy
Y Zeng, Qing Gu, Dan Li, et al.
Acta Pharmacologica Sinica (2024) Vol. 45, Iss. 12, pp. 2455-2473
Closed Access | Times Cited: 4
A chemotherapy nano-booster unlocks wider therapeutic window for prostate cancer treatment
Rui Liao, Yuequan Wang, Ziqi Lin, et al.
Acta Pharmaceutica Sinica B (2025)
Open Access
The immune-reinforcements of Lenvatinib plus anti-PD-1 and their rationale to unite with TACE for unresectable hepatocellular carcinoma treatment
Jiayun Jiang, Hui Zhang, Yanjiao Ou, et al.
Immunology Letters (2025), pp. 107003-107003
Closed Access
Luminescent Binuclear Pd (II) N^C^N‐Pincer Complexes With N^N Bridging Ligand
Xiaping Zhu, Yunjun Shen, Yuzhen Zhang
Applied Organometallic Chemistry (2025) Vol. 39, Iss. 5
Closed Access
Self‐Immolated Nanoadjuvant for In Situ Vaccination Immunotherapy of Colorectal Cancer
Weiqi Wang, Qiwen Zhu, Yilan Jin, et al.
Advanced Healthcare Materials (2023) Vol. 12, Iss. 23
Closed Access | Times Cited: 7
Page 1 - Next Page

Scroll to top